Paris, September 4th, 2023 – Unicancer and Quinten Health have just announced the launch of a global public-private consortium, open to the healthcare industry, dedicated to the development and use of digital twins of real-life patients to de-risk and accelerate late-stage clinical trials, to better differentiate and position new compounds in development, and to anticipate their real-life medical and economic impact. The first disease of focus is lung cancer.
Lung cancer is the leading cause of cancer mortality world wide and the 3rd most frequent cancer. While biomedical research in lung cancer is steadily progressing, the probability of success of clinical trials is still low, and translating innovation into public health impact remains particularly difficult.
“Real-world patient simulators will enable the pharmaceutical industry to better anticipate clinical trials results and consequently better position their new compounds within the current patient care. We are actioning multiple workstreams to engage with regulatory and HTA so to ensure we are developing regulatory-grade reference models, to serve patients first, and inform both public and private decision makers”, says Billy Amzal, CEO of Quinten Health.
“Unicancer is a major global player in cancer research. We are delighted to contribute to the development of this new generation of patients simulators, to improve and personalize patient care, and to focus research efforts on the most urgent and least covered needs“, adds Prof. Jean-Yves Blay, President of Unicancer.
“The understanding of pathophysiological mechanisms and the discovery of new drugs has never progressed so rapidly. However, the heterogeneity of patients and real-life treatments makes it complex and dynamic to rapidly put research and innovation to practical use in patient care. Thanks to the data and experts in the Unicancer network, we’re going to train our algorithms to model and simulate this complexity in order to reduce uncertainties and development costs, and maximize the impact for each patient“, adds Alexandre Templier, President of Quinten Health
“We are excited about this collaboration that paves the way for a new era of treatment personalization, promising significant medical advancements. This initiative also reflects Unicancer’s ongoing commitment to clinical excellence and cutting-edge research for the benefit of patients“, concluded Sophie Beaupère, General Delegate of Unicancer.
